Business
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this yearPre-clinical data from BDTX-1535, BRAF,
About this update from Black Diamond Therapeutics, Inc.
[{"type":"text","content":"Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this yearPre-clinical data from BDTX-1535, BRAF, and FGFR programs presented at AACR-NCI-EORTC (ANE) International ConferenceStrategic partnership established with OpenEye to accelerate drug discovery efforts through cloud-based molecular dynamics technologyCash, cash equivalents, and investments of $235.0 million as of September 30, 2021, expected to be sufficient to fund operations into the second half of 2023 CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “Black Diamond’s approach remains deeply rooted in our proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine, which leverages population-level genetic sequencing that allows for the identification of novel oncogenic mutations. We are well-positioned to advance differentiated MasterKey programs across a range of oncogenic targets for patient populations with unmet need,” said David Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. “We are excited by the continuing progression of our pipeline of MasterKey inhibitor programs, including the BDTX-189 MasterKey-01 study, our BDTX-1535 program with an IND filing anticipated by the first half of 2022, and our BRAF and fibroblast growth factor receptor (FGFR) programs.” Recent Developments BDTX-189: Black Diamond remains on-track with preparations for initiating the Phase 2 portion of the MasterKey-01 Phase 1/2 study of BDTX-189 by the end of 2021. The Company completed the Phase 1 dose-escalation portion of the study and has selected the recommended Phase 2 dose for BDTX-189. BDTX-1535: Black Diamond continues to advance BDTX-1535 through IND-enabling studies and expects to file an IND application by the first half of 2022.In October 2021, Black Diamond presented pre-clinical data for BDTX-1535 at the ANE International Conference: In cell-based assays, BDTX-1535 achieved potent and selective inhibition of a range of EGFR mutations expressed in glioblastoma (GBM) and non-small cell lung cancer (NSC...